EQ (Equillium) Beta: 2.6760 (As of Jun. 24, 2026)


EQ Equillium Inc EQ
28 GF Score
Price $2.88
GF Value $0.10
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Equillium Beta?

Equillium EQ +1.23% 28 Beta is 2.6760 as of Jun. 24, 2026. GuruFocus rates EQ with a GF Score™ of 28/100 and a GF Value™ of $0.10 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Equillium's Beta is 2.6760.


Equillium  (NAS:EQ) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Equillium Beta Related Terms


Equillium Beta Historical Data

* Premium members only.

The historical data trend for Equillium's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Equillium Beta Chart

Equillium Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only 0.87 1.21 0.91 2.19 3.56

Equillium Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.53 2.37 3.07 3.56 3.10

EQ vs MDWD, DTIL, TLSA: Beta Comparison

For the Biotechnology subindustry, Equillium's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Equillium Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Equillium's Beta distribution charts can be found below:

* The bar in red indicates where Equillium's Beta falls into.


EQ
28GF Score
Equillium Inc EQ
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Equillium Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 2.6760 mean?
Equillium (EQ) has a Beta of 2.6760 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Equillium and its competitors.
Is Equillium's Beta too high?
Equillium's current Beta is 2.6760. Overall, Equillium has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Equillium's Beta compare to MDWD and DTIL?
Equillium's Beta of 2.6760 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Equillium and its competitors. Equillium's current Beta is 2.6760. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Equillium stock overvalued right now?
Based on GuruFocus' analysis, Equillium (EQ) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.10, compared to a current price of $2.88 — trading 2775% above its estimated fair value. The current Beta is 2.6760. Equillium's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Equillium (EQ), the current Beta is 2.6760 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Equillium (EQ) Overvalued in 2026?

Based on GuruFocus' analysis, Equillium stock appears to be overvalued. The current stock price of $2.88 is trading 2775% above its estimated GF Value™ of $0.10. GuruFocus considers Equillium to be Significantly Overvalued.

Key valuation signals for EQ:

  • Beta: 2.6760
  • GF Value™: $0.10 vs. price of $2.88 (2775% above fair value)
  • GF Score™: 28/100 with 3 warning signs

No single metric tells the full story. See the EQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Equillium Business Description

Other Exchanges 0A4D:UK0FY:Germany
Address 2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
28GF Score

Get the complete analysis for EQ

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.88
Price
$0.10
GF Value